Christian Heßlinger

1.4k total citations · 1 hit paper
33 papers, 1.0k citations indexed

About

Christian Heßlinger is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Molecular Biology. According to data from OpenAlex, Christian Heßlinger has authored 33 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 11 papers in Physiology and 7 papers in Molecular Biology. Recurrent topics in Christian Heßlinger's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (13 papers), Nitric Oxide and Endothelin Effects (7 papers) and Pulmonary Hypertension Research and Treatments (5 papers). Christian Heßlinger is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (13 papers), Nitric Oxide and Endothelin Effects (7 papers) and Pulmonary Hypertension Research and Treatments (5 papers). Christian Heßlinger collaborates with scholars based in Germany, United States and United Kingdom. Christian Heßlinger's co-authors include R. Gary Sawers, Shirley A. Fairhurst, Andreas Strub, Rainer Boer, Wolf‐Rüdiger Ulrich, Franziska Herrmann, Irmgard Ziegler, Lutz Wollin, Martin D. Lehner and Alex F. Chen and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Circulation.

In The Last Decade

Christian Heßlinger

28 papers receiving 1.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis

2022 139 citations Luca Richeldi, Arata Azuma et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christian Heßlinger Germany	16	379	326	298	113	101	33	1.0k
María Clara Franco United States	20	539 1.4×	100 0.3×	314 1.1×	126 1.1×	101 1.0×	45	1.2k
Yu‐Chin Lien United States	17	485 1.3×	157 0.5×	110 0.4×	76 0.7×	64 0.6×	30	994
Xiaoying Ma China	20	632 1.7×	147 0.5×	162 0.5×	100 0.9×	42 0.4×	108	1.3k
Carla Pignatti Italy	19	807 2.1×	136 0.4×	157 0.5×	68 0.6×	155 1.5×	46	1.2k
John J. LaPres United States	22	721 1.9×	129 0.4×	192 0.6×	135 1.2×	61 0.6×	46	1.4k
Nicolas Abello France	15	399 1.1×	181 0.6×	118 0.4×	58 0.5×	78 0.8×	28	835
Neal S. Gould United States	14	494 1.3×	144 0.4×	288 1.0×	83 0.7×	196 1.9×	19	1.1k
Peter J. Bungay United Kingdom	18	428 1.1×	188 0.6×	99 0.3×	38 0.3×	60 0.6×	35	948
Philippe Bécuwe France	23	834 2.2×	108 0.3×	161 0.5×	99 0.9×	65 0.6×	42	1.4k
Linda Connelly United States	18	669 1.8×	230 0.7×	307 1.0×	420 3.7×	95 0.9×	23	1.7k

Countries citing papers authored by Christian Heßlinger

Since Specialization

Citations

This map shows the geographic impact of Christian Heßlinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christian Heßlinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christian Heßlinger more than expected).

Fields of papers citing papers by Christian Heßlinger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christian Heßlinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christian Heßlinger. The network helps show where Christian Heßlinger may publish in the future.

Co-authorship network of co-authors of Christian Heßlinger

This figure shows the co-authorship network connecting the top 25 collaborators of Christian Heßlinger. A scholar is included among the top collaborators of Christian Heßlinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christian Heßlinger. Christian Heßlinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Todd, Jamie L., Megan L. Neely, Robert J. Kaner, et al.. (2024). Associations of circulating matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases with clinically relevant outcomes in idiopathic pulmonary fibrosis: Data from the IPF-PRO Registry. PLoS ONE. 19(10). e0312044–e0312044.

Summer, Ross, Jamie L. Todd, Megan L. Neely, et al.. (2024). Circulating metabolic profile in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Respiratory Research. 25(1). 58–58. 15 indexed citations

Bentink, Stefan, Christian Heßlinger, Thomas B. Leonard, et al.. (2024). Utility of the 52-Gene Risk Score to Identify Patients with Idiopathic Pulmonary Fibrosis at Greater Risk of Mortality in the Era of Antifibrotic Therapy. Lung. 202(5). 595–599. 1 indexed citations

Todd, Jamie L., Hongyu Zhao, Yi Liu, et al.. (2023). Integrative multi-omics analysis reveals novel idiopathic pulmonary fibrosis endotypes associated with disease progression. Respiratory Research. 24(1). 141–141. 15 indexed citations

Herrmann, Franziska, et al.. (2022). BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis. Frontiers in Pharmacology. 13. 838449–838449. 79 indexed citations

Todd, Jamie L., Megan L. Neely, Robert Overton, et al.. (2022). Association of Circulating Proteins with Death or Lung Transplant in Patients with Idiopathic Pulmonary Fibrosis in the IPF-PRO Registry Cohort. Lung. 200(1). 11–18. 5 indexed citations

Richeldi, Luca, Arata Azuma, Vincent Cottin, et al.. (2022). Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis. Journal of Comparative Effectiveness Research. 12(1). 2 indexed citations

Todd, Jamie L., Richard Vinisko, Yi Liu, et al.. (2020). Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort. BMC Pulmonary Medicine. 20(1). 64–64. 68 indexed citations

Todd, Jamie L., Megan L. Neely, Robert Overton, et al.. (2019). Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry. Respiratory Research. 20(1). 227–227. 60 indexed citations

10.

Tiso, Mauro, et al.. (2008). BYK191023 (2-[2-(4-Methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine) Is an NADPH- and Time-Dependent Irreversible Inhibitor of Inducible Nitric-Oxide Synthase. Molecular Pharmacology. 73(4). 1244–1253. 8 indexed citations

11.

Heßlinger, Christian, Martin D. Lehner, Andreas Strub, et al.. (2008). O66. The highly selective iNOS inhibitor BYK402750 exerts potent anti-inflammatory effects in a mouse model of cigarette smoke-induced inflammation. Nitric Oxide. 19. 35–35. 2 indexed citations

12.

Lehner, Martin D., Degenhard Marx, Rainer Boer, et al.. (2006). In Vivo Characterization of the Novel Imidazopyridine BYK191023 [2-[2-(4-Methoxy-pyridin-2-yl)-ethyl]-3 H-imidazo[4,5-b]pyridine], a Potent and Highly Selective Inhibitor of Inducible Nitric-Oxide Synthase. Journal of Pharmacology and Experimental Therapeutics. 317(1). 181–187. 11 indexed citations

13.

Strub, Andreas, Wolf‐Rüdiger Ulrich, Christian Heßlinger, et al.. (2005). The Novel Imidazopyridine 2-[2-(4-Methoxy-pyridin-2-yl)-ethyl]-3H-imidazo[4,5-b]pyridine (BYK191023) Is a Highly Selective Inhibitor of the Inducible Nitric-Oxide Synthase. Molecular Pharmacology. 69(1). 328–337. 32 indexed citations

14.

Gilchrist, Mark, Christian Heßlinger, & A. Dean Befus. (2003). Tetrahydrobiopterin, a Critical Factor in the Production and Role of Nitric Oxide in Mast Cells. Journal of Biological Chemistry. 278(50). 50607–50614. 28 indexed citations

15.

Jansen, Pernille, et al.. (2003). Tetrahydrobiopterin precursor sepiapterin provides protection against neurotoxicity of 1‐methyl‐4‐phenylpyridinium in nigral slice cultures. Journal of Neurochemistry. 85(1). 214–223. 25 indexed citations

16.

Lookingland, Keith J., Gregory D. Fink, Christian Heßlinger, et al.. (2003). Gene Transfer of Human Guanosine 5′-Triphosphate Cyclohydrolase I Restores Vascular Tetrahydrobiopterin Level and Endothelial Function in Low Renin Hypertension. Circulation. 108(10). 1238–1245. 114 indexed citations

17.

Bauer, M., Morten Meyer, Christian Heßlinger, et al.. (2002). Glial cell line‐derived neurotrophic factor up‐regulates GTP‐cyclohydrolase I activity and tetrahydrobiopterin levels in primary dopaminergic neurones. Journal of Neurochemistry. 82(5). 1300–1310. 21 indexed citations

18.

Ziegler, Irmgard, et al.. (2000). Development of the Pteridine Pathway in the Zebrafish,Danio rerio. Journal of Biological Chemistry. 275(25). 18926–18932. 55 indexed citations

19.

Heßlinger, Christian & R. Gary Sawers. (1998). The tdcE Gene in Escherichia Coli Strain W3110 is Separated from the Rest of the tdc Operon by Insertion of IS5 Elements. DNA sequence. 9(3). 183–188. 6 indexed citations

20.

Heßlinger, Christian, Elisabeth Kremmer, Lothar Hültner, Marius Ueffing, & Irmgard Ziegler. (1998). Phosphorylation of GTP Cyclohydrolase I and Modulation of Its Activity in Rodent Mast Cells. Journal of Biological Chemistry. 273(34). 21616–21622. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact